<DOC>
	<DOCNO>NCT02659501</DOCNO>
	<brief_summary>Objectives : 1 . To evaluate effect liposomal bupivacaine postoperative pain level . 2 . To evaluate effect liposomal bupivacaine postoperative opioid consumption opioid related adverse event . 3 . To evaluate effect liposomal bupivacaine length hospital stay . 4 . To evaluate effect liposomal bupivacaine patient satisfaction postoperative pain control . 5 . To evaluate effect liposomal bupivacaine overall patient satisfaction .</brief_summary>
	<brief_title>Liposomal Bupivacaine Implant Based Breast Reconstruction</brief_title>
	<detailed_description>Objectives : 1 . To evaluate effect liposomal bupivacaine postoperative pain level . 2 . To evaluate effect liposomal bupivacaine postoperative opioid consumption opioid related adverse event . 3 . To evaluate effect liposomal bupivacaine length hospital stay . 4 . To evaluate effect liposomal bupivacaine patient satisfaction postoperative pain control . 5 . To evaluate effect liposomal bupivacaine overall patient satisfaction . The objective project evaluate role liposomal bupivacaine postoperative pain control follow tissue expander implant base breast reconstruction . This unique formulation bupivacaine lend drug long duration action reduce plasma bupivacaine concentration compare plain bupivacaine . This agent demonstrate safe , well tolerate , effective number different clinical application . However , role yet evaluate context breast reconstruction . Thus , author propose first , randomize , control clinical trial liposomal bupivacaine postoperative pain management follow tissue expander implant base breast reconstruction . Patients stratify two study group . Patients Group 1 ( Bupivacaine ) treat intraoperatively injection 0.5 % bupivacaine epinephrine 1:200,000 , 50 mg deliver perform field block pocket . This current standard care . Patients Group 2 ( Liposomal Bupivacaine ) treat intraoperatively injection 1.33 % liposomal bupivacaine , 133 mg deliver perform field block breast pocket . This experimental intervention . Postoperatively , investigator assess pain level , opioid consumption , opioid related adverse event , length stay , satisfaction . The finding study allow author well elucidate role liposomal bupivacaine expander/implant base breast reconstruction . In , may allow author identify ideal pain regimen patient . This hold important implication , potential reduce postoperative pain , opioid consumption , opioid related adverse event , length stay , patient satisfaction .</detailed_description>
	<mesh_term>Pain , Postoperative</mesh_term>
	<mesh_term>Bupivacaine</mesh_term>
	<mesh_term>Diazepam</mesh_term>
	<mesh_term>Morphine</mesh_term>
	<mesh_term>Hydrocodone</mesh_term>
	<mesh_term>Acetaminophen , hydrocodone drug combination</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<mesh_term>Epinephrine</mesh_term>
	<mesh_term>Racepinephrine</mesh_term>
	<mesh_term>Epinephryl borate</mesh_term>
	<criteria>Women undergo immediate unilateral bilateral tissueexpander breast reconstruction follow skinsparing nipplesparing mastectomy Women unable give inform consent participate study Women document history hypersensitivity reaction localanesthetic agent Women diagnosis chronic pain disorder fibromyalgia , chronic migraine headache , psychiatric disorder depression anxiety Women currently pregnant Women undergo tissue expander base breast reconstruction muscle flap combination tissue expander Women impair hepatic function</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Breast reconstruction</keyword>
	<keyword>Bupivacaine</keyword>
	<keyword>Liposomal bupivacaine</keyword>
	<keyword>Postoperative analgesia</keyword>
</DOC>